Back to results
US 11,918,556 B2Granted
Treatment of circadian rhythm disorders
AssigneeVanda Pharmaceuticals Inc.
InventorsMarlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Claims3
A method of treating a patient for a circadian rhythm disorder or a sleep disorder wherein the patient is being treated with a beta-adrenergic receptor antagonist, the method comprising:
- discontinuing treatment with the beta-adrenergic receptor antagonist;
- and then
- administering to the patient with 20 mg tasimelteon once daily about one-half hour to about one-and-one-half hours before the target bedtime;
- thereby avoiding decreased efficacy of tasimelteon treatment due to co-administration with the beta-adrenergic receptor antagonist.
1 more element
Dependencies are inferred from the claim text.